Chiesi in-licenses DPP1 inhibitor from Haisco Pharma

20 November 2023

Italian family-owned drugmaker Chiesi Farmaceutici has added another investigational product to its list of in-licensed investigational meds, as well as the $1.25 billion acquisition of Anglo-Irish firm Amryt Pharma, this year alone.

This time, Chiesi said it has executed a license agreement with China-based Haisco Pharmaceutical to develop, manufacture, and commercialize outside China and adjacent territories (Hong Kong SAR, Macau SAR and Taiwan District) HSK31858, a novel, reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Chiesi explained that HSK31858 is an oral, potent, and highly selective small molecule DPP1 inhibitor currently in Phase II trials in China with the potential to be an anti-inflammatory agent in bronchiectasis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK